The call highlights significant progress in study adjustments and financial management, with strong engagement from new clinical sites. However, challenges with legacy site performance and patient enrollment were notable issues.

Company Guidance -

Q2 2025

During the Talphera First Quarter 2025 Financial Results Conference Call, the company provided key guidance metrics, emphasizing a strategic focus on enhancing the NEPHRO CRRT trial. Notably, the trial size was reduced from 166 to 70 patients, and the company activated additional high-volume sites, which include 3 new sites with 5 more expected by mid-year, to expedite patient enrollment. Talphera also completed a PIPE financing, structured in three tranches, with a total commitment of $14.8 million contingent on enrollment milestones. Financially, the company reduced its cash operating expense guidance to a range of $17 million to $19 million for 2025, down from prior estimates, and reported a first-quarter cash balance of $5.4 million. These changes, alongside the potential compassionate use IDE discussions, are intended to support the completion of the study by year-end, with an FDA approval for Niyad anticipated in 2026.

FDA Approval for NEPHRO CRRT Trial Adjustments

The trial received FDA approval for a significantly decreased study size from 166 to 70 patients, removal of certain exclusion criteria, and activation of additional high-volume sites to accelerate enrollment.

Successful PIPE Financing

Completed a PIPE financing structured in three equal tranches of $4.925 million, with conditions that are expected to be achieved within the year.

Cost Reduction and Financial Management

Reduced cash operating expenses from $4.2 million in Q1 2024 to $2.9 million in Q1 2025, with further reductions in personnel expenses and other administrative costs.

High Engagement with New Clinical Sites

Added 3 new sites with 5 more expected by mid-year, all fitting the new target profile, enhancing engagement and efficiency in contracting.

Talphera (TLPH) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

TLPH Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 18, 2025	2025 (Q2)	-0.13 / -	-0.15	―	―	―
May 14, 2025	2025 (Q1)	- / -0.10	-0.16	37.50% (+0.06)	―
Mar 31, 2025	2024 (Q4)	-0.14 / -0.10	-0.16	37.50% (+0.06)	―
Nov 13, 2024	2024 (Q3)	-0.19 / -0.13	-0.08	-62.50% (-0.05)	―
Aug 14, 2024	2024 (Q2)	-0.21 / -0.15	-0.41	63.41% (+0.26)	―
May 14, 2024	2024 (Q1)	-0.25 / -0.16	-0.75	78.67% (+0.59)	―
Mar 06, 2024	2023 (Q4)	-0.20 / -0.25	-1	75.00% (+0.75)	―
Nov 08, 2023	2023 (Q3)	-0.28 / -0.08	-0.94	91.49% (+0.86)	―
Aug 10, 2023	2023 (Q2)	-0.53 / -0.41	9.6	-104.27% (-10.01)	―
May 10, 2023	2023 (Q1)	-0.79 / -0.75	-1.2	37.50% (+0.45)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

TLPH Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 14, 2025	$0.51	$0.49	-3.92%
Mar 31, 2025	$0.50	$0.53	+6.00%
Nov 13, 2024	$0.89	$0.66	-25.84%
Aug 14, 2024	$0.86	$0.87	+1.16%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Talphera (TLPH) report earnings?

Talphera (TLPH) is schdueled to report earning on Aug 18, 2025, After Close (Confirmed).

What is Talphera (TLPH) earnings time?

Talphera (TLPH) earnings time is at Aug 18, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is TLPH EPS forecast?

TLPH EPS forecast for the fiscal quarter 2025 (Q2) is -0.13.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing